Podcasts
Episode 150: Review of Novartis False Claims Act and Anti-Kickback Settlements for $729 Million
Novartis is the new poster-child of corporate misconduct. In the space of two weeks, Novartis settled domestic False Claims Act and Anti-Kickback violations for $729 million, and settled FCPA violations for foreign bribery for $337 million. In the domestic False Claims Act and AKS cases, Novartis resolved two